Pro-Dex (PDEX) to Release Earnings on Wednesday

Pro-Dex (NASDAQ:PDEX) is expected to post its Q3 2026 results before the market opens on Wednesday, April 29th. Analysts expect Pro-Dex to post earnings of $0.62 per share and revenue of $17.90 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earning report page for the latest details on the call scheduled for Friday, May 8, 2026 at 4:00 PM ET.

Pro-Dex (NASDAQ:PDEX) last released its earnings results on Thursday, January 29th. The medical instruments supplier reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.07. Pro-Dex had a return on equity of 22.53% and a net margin of 15.73%.The company had revenue of $18.66 million for the quarter, compared to analysts’ expectations of $17.30 million.

Pro-Dex Trading Down 0.3%

NASDAQ:PDEX opened at $51.96 on Tuesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.03 and a quick ratio of 2.25. Pro-Dex has a fifty-two week low of $23.47 and a fifty-two week high of $70.25. The stock’s 50-day moving average is $48.00 and its two-hundred day moving average is $40.66. The stock has a market cap of $166.79 million, a PE ratio of 15.28 and a beta of -0.11.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Pro-Dex in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $56.00.

Institutional Investors Weigh In On Pro-Dex

Several large investors have recently made changes to their positions in PDEX. Geode Capital Management LLC grew its stake in shares of Pro-Dex by 93.2% in the 2nd quarter. Geode Capital Management LLC now owns 51,668 shares of the medical instruments supplier’s stock valued at $2,255,000 after buying an additional 24,927 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Pro-Dex by 67.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 35,877 shares of the medical instruments supplier’s stock valued at $1,566,000 after buying an additional 14,479 shares in the last quarter. Punch & Associates Investment Management Inc. grew its stake in shares of Pro-Dex by 42.1% in the 3rd quarter. Punch & Associates Investment Management Inc. now owns 48,608 shares of the medical instruments supplier’s stock valued at $1,645,000 after buying an additional 14,408 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Pro-Dex in the 1st quarter valued at approximately $321,000. Finally, LPL Financial LLC bought a new stake in shares of Pro-Dex in the 4th quarter valued at approximately $228,000. Institutional investors own 15.28% of the company’s stock.

Pro-Dex Company Profile

Pro-Dex, Inc is a designer and manufacturer of precision drive systems and fluid management products serving the dental, medical, industrial and energy markets. The company specializes in high-speed, brushless micromotors and controllers, as well as pneumatic and fluid control devices, providing both standard and custom-engineered solutions for original equipment manufacturers.

Its product portfolio includes high-speed dental handpieces, turbine systems, rotary and reciprocating micro-drives, along with integrated fluid delivery systems.